Sugi Predict

Sugi Predict / Compounds / SCHEMBL6475466

SCHEMBL6475466

SCHEMBL6475466

CC(=O)c1ccc2[nH]c([S+]([O-])Cc3ccccc3N(C)C)nc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATP4A P20648 1/20 0.39
▸ ATP4B P51164 1/20 0.39
▸ SLC40A1 Q9NP59 1/20 0.33
▸ IL4I1 Q96RQ9 1/20 0.32
▸ ALDH1A1 P00352 5/20 0.32
▸ HPGD P15428 2/20 0.32
▸ LMNA P02545 1/20 0.32
▸ KMT2A Q03164 2/20 0.31
▸ GAA P10253 1/20 0.31
▸ HDAC6 Q9UBN7 1/20 0.31
▸ RXFP1 Q9HBX9 1/20 0.31
▸ NPC1 O15118 2/20 0.31
▸ RAB9A P51151 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KDM4E B2RXH2 2/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ PKM P14618 1/20 0.30
▸ FOXO1 Q12778 1/20 0.30
▸ HTR1A P08908 1/20 0.30
▸ HTR1D P28221 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475474 0.92 ATP4A (0.39) ATP4AATP4BALDH1A1HPGDHDAC6
SCHEMBL9678832 0.92 ATP4A (0.39) ATP4AATP4BSLC40A1ALDH1A1HPGD
SCHEMBL9677052 0.90 ALDH1A1 (0.41) ATP4AATP4BALDH1A1HPGDLMNA
SCHEMBL9395685 0.89 SMN1; SMN2 (0.39) ATP4AATP4BALDH1A1HPGDLMNA
SCHEMBL6482665 0.85 ATP4A (0.39) ATP4AATP4BSLC40A1LMNAGAA
SCHEMBL9396516 0.84 ATP4A (0.40) ATP4AATP4BALDH1A1HPGDLMNA
SCHEMBL10697978 0.83 ATP4A (0.38) ATP4AATP4BSLC40A1HSD17B10
SCHEMBL9395890 0.83 ATP4A (0.39) ATP4AATP4BALDH1A1HPGDLMNA
SCHEMBL9395786 0.83 ATP4A (0.39) ATP4AATP4BALDH1A1HPGDLMNA
SCHEMBL3689535 0.82 ATP4A (0.52) ATP4AATP4BSLC40A1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents MOORMAN ALAN E (US) 2001-11-29 — — US claimed
US-5945425-A ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE G.D. SEARLE & CO. (US) 1999-08-31 — — US claimed
WO-1995029897-A1 METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS G.D. SEARLE & CO. (US) 1995-11-09 — — WO claimed
JP-62145069-A — — None — — JP disclosed
US-6906078-B2 Method of using (H+/K+) ATPase inhibitors as antiviral agents PHARMACIA CORPORATION (US) 2005-06-14 — — US disclosed
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents MOORMAN ALAN E (US) 2001-11-29 — — US disclosed
US-5945425-A ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE G.D. SEARLE & CO. (US) 1999-08-31 — — US disclosed
WO-1995029897-A1 METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS G.D. SEARLE & CO. (US) 1995-11-09 — — WO disclosed
JP-S62145069-A BENZIMIDAZOLE DERIVATIVE TAISHO PHARMACEUT CO LTD 1987-06-29 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents ATP4A, ATP1A1, ATP1A4 ATP4A 1/4885ATP4B 8/4885SLC40A1 3152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.